Fig 1: The osteogenic ability of various metallic implants is positively associated with TRIM30a expression. (A) Masson staining shows bone formation around various implants at 7 days post-implantation. Scale bar, 500 μm (up); 100 μm (below). (B) Quantification of new bone area rate (BA%), n = 6. (C) Heatmap of the bulk RNA seq shows gene expressions related to immune response, skeletal system development, and bone remodeling across different groups. (D) Box plot of proteomics analysis shows increased expression of TRIM30a for implants with superior osseointegration at 1 day after implantation. (E) Volcano plot of upregulated differentially expressed proteins (DEPs) in the SR implant compared to other implants indicates higher expression of TRIM30a. Changes greater than 2-fold are depicted outside the boundary lines. p < 0.05, false discovery rate (FDR) < 0.05. (F, G) Immunohistochemistry staining and quantitative analysis of TRIM30a-positive cells (brown) around implants at 7 days post-implantation. Scale bar, 100 μm, n = 5. (H) Correlation regression analysis of the expression of TRIM30a and BA%. The level of TRIM30a expression in different groups was positively associated with the area of new bone formation. (I–L) Three-dimensional reconstruction images (I) and quantitative analysis (J–L) of micro-CT, show a decreased bone formation (BV/TV%, BS/BV%, and Tb.Th) in TRIM30a-KO mice compared to wild-type (TRIM30a-WT) controls at 14 days post-implantation (BV/TV: bone volume/total volume; BS/BV: bone surface/bone volume; Tb.Th: trabecular thickness, n = 6). (M, N) Representative images of Masson staining (M) and quantification analysis (N), show less new bone formation in TRIM30a-KO mice compared to wild-type (TRIM30a-WT) controls. Scale bar: 500 μm (left); 150 μm (right), n = 6. Data are means ± s.e.m. and ANOVA with Tukey's post-hoc correction for multiple comparisons, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig 2: TRIM30a downregulated NETs formation through NF-κB/NLRP3 pathways. (A) Neutrophil cell viability in response to the treatment with the E3 ligase agonist (PAR) and antagonist (K17), n = 6. (B) Representative SEM images of NETosis on the SR implant surface following different treatments. Scale bar: 10 μm. (C) Immunofluorescent staining about the release of NE (red) and DNA components (green) in neutrophils after different treatments. Scale bar: 50 μm. (D, E) Immunofluorescent intensity analysis of NE and SYTOX green staining, n = 6 independent experimental replicates. (F) Quantification of intercellular ROS generation in neutrophils, n = 6 independent experimental replicates. (G–I) Representative immunoblot images and semi-quantitative analysis of NE and MPO protein levels in neutrophils cultured under different conditions, n = 6 independent experimental replicates. (J) Representative SEM images showing the formation of NETs on surfaces by neutrophils with (WT) or without (KO) Trim30a expression. Scale bar: 10 μm. (K–M) Fluorescence intensity of SYTOX Green staining (K), dsDNA release level (L), and intracellular ROS release level (M) in WT and KO neutrophils, n = 6 independent experimental replicates. (N, O) Representative immunofluorescent staining images and semi-quantitative analysis of NETosis in WT and KO neutrophils cultured on the implant surfaces (H3cit, red; NE, green; nucleus, blue). Scale bar: 50 μm, n = 6 independent experimental replicates. (P, Q) Absence of NETs (Ly6G+MPO+H3cit+, indicated by white arrow) in peri-implant bone tissue between WT and KO mice by immunofluorescent staining (P), and quantification of the number of NETs around the implant (Q). Scale bar: 50 μm (left); 10 μm (right), n = 5. (R, S) Absence of NETs in peri-implant bone tissue between WT and N-CKO mice (R) by immunofluorescent staining, and quantification of the number of NETs around the implant (S). Scale bar: 50 μm (left); 10 μm (right), n = 5. T) Transcriptional levels of Nlrp3, Asc, Caspase-1, Il-1β, and Tnf-α in WT and KO neutrophils, n = 5 independent experimental replicates. (U–Z) Representative immunoblot images and semi-quantitative analysis of protein levels in the NF-κB and NLRP3 signaling pathways in WT and KO neutrophils, n = 5 independent experimental replicates. (AA) Schematic diagram illustrating the potential mechanism by which TRIM30a regulates NETosis. Data are means ± s.e.m. and ANOVA with Tukey's post-hoc correction for multiple comparisons, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Panel aa created with BioRender.com. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig 3: TRIM30a enhanced dsDNA perception in macrophages via cGAS-STING signaling pathway. (A) Transcriptional level of genes in the cGAS-STING signaling pathway, including Sting, Ifit1, Ifit2, Isg15, and Oas3, in the ctrl, dsDNA, and dsDNA + DNase I groups. (ctrl: macrophages without any treatment; dsDNA: macrophages treated with dsDNA; dsDNA + DNase I: macrophages treated with dsDNA and DNase I.) (B) Transcriptional level of genes in the cGAS-STING signaling pathway in the ctrl, dsDNA, and dsDNA + siRNA groups. (ctrl: normal macrophages without any treatment; dsDNA: normal macrophages treated with dsDNA; dsDNA + siRNA: macrophages with Trim30a RNA interference treated with dsDNA.) (C) Representative immunoblot images of proteins in the cGAS-STING and NF-κB signaling pathways in the ctrl, dsDNA, and dsDNA + siRNA groups. (D–I) Semi-quantitative analysis of protein levels in the cGAS-STING and NF-κB signaling pathways. (J–L) Secretion of IFN-β, IL-6, and TNF-α from the ctrl, dsDNA, and dsDNA + siRNA groups. n = 6 independent experimental replicates. Data are means ± s.e.m. and ANOVA with Tukey's post-hoc correction for multiple comparisons, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Fig 4: TRIM30a deficiency in neutrophils and macrophages impaired osseointegration, and its expression was influenced by different implants. (A) Peri-implant tissues of various implants at 3 days post-implantation underwent scRNA-seq. t-SNE plot illustrates cellular heterogeneity with the identification of 10 clusters: (1) monocytes (MC), (2) neutrophils (NEU), (3) macrophages (MAC), (4) B cells (BC), (5) T cells (TC), (6) dendritic cells (DC), (7) Erythroid cells (EC), (8) Basophils (BS), (9) Natural killer cells (NK), and (10) Hematopoietic stem progenitor cells (HSC). (B) scRNA-seq analysis of gene expression levels of Trim30a across various cell clusters. (C) Three-dimensional reconstruction of bone formation at 14 days post-implantation in wild-type (WT) and neutrophil-specific Trim30a conditional knockout (N-CKO) mice. N-CKO, conditional knockout of Trim30a in neutrophils. (D–F) Quantitative analysis of BV/TV%, BS/BV% and Tb.Th in WT and N-CKO mice, n = 5. (G and H) Representative images and quantification analysis of new bone formation area using Masson staining. Scale bar: 500 μm (left), 100 μm (right); n = 5. (I) Three-dimensional reconstruction of bone formation at 14 days post-implantation in WT and macrophage-specific Trim30a conditional knockout (M-CKO) mice. M-CKO, Trim30a conditional knock-out in macrophages. (J–L) Quantitative analysis of BV/TV%, BS/BV% and Tb.Th in WT and M-CKO mice, n = 5. (M, N) Representative images and quantification analysis of new bone formation area via hematoxylin and eosin (H&E) staining. Scale bar. 500 μm (left), 100 μm (right); n = 5. (O, P) Violin plots depicting the transcriptional levels of Trim30a in neutrophils (O) and G0-G5 subclusters (P) across the five groups. (Q) Gene pod map illustrated the differences in gene density of neutrophils comparing SR to SS groups. (R, S) Violin plots showed the transcriptional levels of Trim30a in macrophages (R) and subclusters (S) across the five groups. t, Gene pod map revealing the differentiation between Trim30a-expressing and non-expressing macrophages in the SR and SS groups. (U–V) Representative immunoblot images and quantitative analysis of TRIM30a expression in neutrophils after cultured on different implant materials, n = 6 independent experimental replicates. (W, X) Representative immunoblot images and quantitative analysis of TRIM30a expression in macrophages after cultured on different implant materials, n = 6 independent experimental replicates. Data are means ± s.e.m. and ANOVA with Tukey's post-hoc correction for multiple comparisons, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Fig 5: Implant biomaterial amplified dsDNA perception by enhancing TRIM30a expression in macrophages. (A) Experimental flow chart illustrating macrophages stimulated with dsDNA which was collected from neutrophils cultured on various implant surfaces (i). (B) Transcriptional levels of genes in the cGAS-STING signaling pathway of macrophages with only dsDNA stimulation (condition i). (C) Representative immunoblot images of proteins in the cGAS-STING signaling pathway of macrophages with only dsDNA stimulation (condition i). (D–F) Semi-quantitative analysis of protein levels in the cGAS-STING signaling pathway of macrophages with only dsDNA stimulation (condition i). (G) Experimental flow chart illustrating macrophages stimulated with dsDNA and directly cultured on various implant surfaces (ii). (H) Transcriptional levels of genes in the cGAS-STING signaling pathway of macrophages (condition ii). (I) Representative immunoblot images of proteins in the cGAS-STING signaling pathway of macrophages (condition ii). (J–O) Semi-quantitative analysis of protein levels of cGAS-STING and NF-κB signaling pathway of macrophages (condition ii). (P–R) Secretion of IFN-β, IL-6, and TNF-α from macrophages stimulated with dsDNA and directly cultured on different implant surfaces (condition ii). A-R macrophages were cultured with various treatments for 3 d, n = 6 independent experimental replicates. Data are means ± s.e.m. and ANOVA with Tukey's post-hoc correction for multiple comparisons, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Supplier Page from Bioss Inc. for TRIM30 Polyclonal Antibody